BACKGROUND AND OBJECTIVES: Insulin resistance is a complication of advanced CKD. Insulin resistance is less well characterized in earlier stages of CKD. The response of the pancreatic β cell, effects on glucose tolerance, and risk of diabetes are not clear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Cardiovascular Health Study included 4680 adults without baseline diabetes. The Chronic Kidney Disease Epidemiology Collaboration creatinine equation was used to obtain the estimated GFR (eGFR). Insulin resistance was evaluated as fasting insulin concentration. The insulin sensitivity index, β cell function, and glucose tolerance were assessed by oral glucose tolerance testing. Incident diabetes was defined as fasting glucose ≥126 mg/dl, nonfasting glucose ≥200 mg/dl, or use of glucose-lowering medications. RESULTS: Mean age was 72.5 years (range, 65-98 years). Mean eGFR was 72.2 (SD 17.1) ml/min per 1.73 m(2). After adjustment, each 10 ml/min per 1.73 m(2) lower eGFR was associated with a 2.2% higher fasting insulin concentration (95% confidence interval [CI], 1.4%, 2.9%; P<0.001) and a 1.1% lower insulin sensitivity index (95% CI, 0.03%, 2.2%; P=0.04). Surprisingly, eGFR was associated with an augmented β cell function index (P<0.001), lower 2-hour glucose concentration (P=0.002), and decreased risk of glucose intolerance (P=0.006). Over a median 12 years' follow-up, 437 participants (9.3%) developed diabetes. eGFR was not associated with the risk of incident diabetes. CONCLUSIONS: Among older adults, lower eGFR was associated with insulin resistance. However, with lower eGFR, β cell function was appropriately augmented and risks of impaired glucose tolerance and incident diabetes were not increased.
BACKGROUND AND OBJECTIVES:Insulin resistance is a complication of advanced CKD. Insulin resistance is less well characterized in earlier stages of CKD. The response of the pancreatic β cell, effects on glucose tolerance, and risk of diabetes are not clear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Cardiovascular Health Study included 4680 adults without baseline diabetes. The Chronic Kidney Disease Epidemiology Collaboration creatinine equation was used to obtain the estimated GFR (eGFR). Insulin resistance was evaluated as fasting insulin concentration. The insulin sensitivity index, β cell function, and glucose tolerance were assessed by oral glucose tolerance testing. Incident diabetes was defined as fasting glucose ≥126 mg/dl, nonfasting glucose ≥200 mg/dl, or use of glucose-lowering medications. RESULTS: Mean age was 72.5 years (range, 65-98 years). Mean eGFR was 72.2 (SD 17.1) ml/min per 1.73 m(2). After adjustment, each 10 ml/min per 1.73 m(2) lower eGFR was associated with a 2.2% higher fasting insulin concentration (95% confidence interval [CI], 1.4%, 2.9%; P<0.001) and a 1.1% lower insulin sensitivity index (95% CI, 0.03%, 2.2%; P=0.04). Surprisingly, eGFR was associated with an augmented β cell function index (P<0.001), lower 2-hour glucose concentration (P=0.002), and decreased risk of glucose intolerance (P=0.006). Over a median 12 years' follow-up, 437 participants (9.3%) developed diabetes. eGFR was not associated with the risk of incident diabetes. CONCLUSIONS: Among older adults, lower eGFR was associated with insulin resistance. However, with lower eGFR, β cell function was appropriately augmented and risks of impaired glucose tolerance and incident diabetes were not increased.
Authors: Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks Journal: JAMA Date: 2003-01-01 Impact factor: 56.272
Authors: L H Kuller; P Velentgas; J Barzilay; N J Beauchamp; D H O'Leary; P J Savage Journal: Arterioscler Thromb Vasc Biol Date: 2000-03 Impact factor: 8.311
Authors: Jing Chen; Paul Muntner; L Lee Hamm; Vivian Fonseca; Vecihi Batuman; Paul K Whelton; Jiang He Journal: J Am Soc Nephrol Date: 2003-02 Impact factor: 10.121
Authors: Iram Ahmad; Leila R Zelnick; Nicole R Robinson; Adriana M Hung; Bryan Kestenbaum; Kristina M Utzschneider; Steven E Kahn; Ian H de Boer Journal: Am J Physiol Endocrinol Metab Date: 2017-01-10 Impact factor: 4.310
Authors: Ting Jia; Ulf Risérus; Hong Xu; Bengt Lindholm; Johan Ärnlöv; Per Sjögren; Tommy Cederholm; Tobias E Larsson; Talat Alp Ikizler; Juan J Carrero Journal: J Clin Endocrinol Metab Date: 2014-11-27 Impact factor: 5.958
Authors: Hong Xu; Xiaoyan Huang; Johan Arnlöv; Tommy Cederholm; Peter Stenvinkel; Bengt Lindholm; Ulf Risérus; Juan Jesús Carrero Journal: Clin J Am Soc Nephrol Date: 2014-01-16 Impact factor: 8.237
Authors: Ranee Chatterjee; Mary L Biggs; Ian H de Boer; Frederick L Brancati; Laura P Svetkey; Joshua Barzilay; Luc Djoussé; Joachim H Ix; Jorge R Kizer; David S Siscovick; Dariush Mozaffarian; David Edelman; Kenneth J Mukamal Journal: J Gerontol A Biol Sci Med Sci Date: 2014-06-03 Impact factor: 6.053
Authors: Halil O Ikizler; Leila Zelnick; John Ruzinski; Laura Curtin; Kristina M Utzschneider; Bryan Kestenbaum; Jonathan Himmelfarb; Ian H de Boer Journal: J Ren Nutr Date: 2015-10-23 Impact factor: 3.655
Authors: Ian H de Boer; Leila Zelnick; Maryam Afkarian; Ernest Ayers; Laura Curtin; Jonathan Himmelfarb; T Alp Ikizler; Steven E Kahn; Bryan Kestenbaum; Kristina Utzschneider Journal: J Am Soc Nephrol Date: 2016-01-28 Impact factor: 10.121